433. Psilocybin reveals diverse antidepressant efficacies across different preclinical models of depression
International Journal of Neuropsychopharmacology September 9, 2026 Z Wang, W Chen, C Hu et al.
Abstract Background Within the rapidly expanding field of psychedelic research, psilocybin, along with its active metabolite psilocin, has emerged as a highly promising candidate in the search for innovative treatments for neuropsychiatric disorders. In this context, preclinical research using animal disease models has produced somewhat inconsistent results when employing standard tests to...